References
- Kent R. S., De Lean A., Lefkowitz R. J. A quantitative analysis of β-Adrenergic receptor interactions: Resolution of high- and low affinity states of the receptor by computer modelling of ligand binding data. Mol. Pharm. 1979; 17: 14–23
- Wregrett K. A., De Lean A. The ternary complex model: its properties and application to ligand interactions with the D2dopamine receptor of the anterior pituitary gland. Mol. Pharmacol. 1984; 26: 214–227
- Freissmuth M., Casey P. J., Gilman A. G. G proteins control diverse pathways of transmembrane signaling. FASEB J. 1989; 3: 2125–2131
- Lahti R. A., Figur L. M., Piercey M. F., Ruppel P. L., Evans D. L. Intrinsic activity determinations at the dopamine D2guanine-nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharm. 1992; 42: 432–438
- Freedman S. B., Dawson G. R., Iversen L. L., Baker R., Hargreaves R. J. The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. Life Sciences 1993; 52: 489–495
- Sharif N. A., Williams G. W., DeSantis L. M. Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]Oxotremorine (OXO) binding to a mixture of M1-M4muscarinic receptors: Use of NMS/OXO-M ratios to group compounds into potential agonists, partial agonists, and antagonist classes. Neurochem. Research 1995; 70: 669–674
- Peterson G. L., Schimerlik M. I. Large scale preparation and characterization of membrane-bound and detergent-solubilized muscarinic acetylcholine receptor from pig atria. Prep. Biochem. 1984; 14: 33–74
- Haddad E. B., Landry Y., Gies J.-P. Sialic acid residues as catalysts for M2-muscarinic agonist-receptor interactions. Mol. Pharmacol. 1990; 37: 682–688
- Haddad E. B., Trifilieff A., Landry Y., Gies J.-P. Heterogeneity of guinea-pig lung muscarinic receptors revealed by [3H]-4-DAMP binding. Pulmonary Pharmacol. 1993; 6: 119–127
- Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem. 1976; 72: 248–254
- Hilf G., Jakobs K. H. Activation of cardiac G-proteins by muscarinic acetylcholine receptors: regulation by Mg2+and Na+ions. Eur. J. Pharmacol. – Mol. Pharm. Sect. 1989; 172: 155–163
- Cheng Y.-C., Prusoff W. H. The relationship between inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973; 22: 3099–3108
- Keen M. Testing models of agonism for G-protein coupled receptors. Tr. Pharm. Sc. 1991; 12: 371–374
- Birsdall N. J.M., Burgen A. S.V., Hulme E. C. The binding of agonists to brain muscarinic receptors. Mol. Pharmacol. 1978; 14: 723–726
- Gies J.-P., Ilien B., Landry Y. Temperature-dependence and heterogeneity of muscarinic agonist and antagonist binding. Biochem. Pharmacol. 1987; 36(16)2589–2597
- Tota M. R., Schimerlik M. I. Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system. Mol. Pharmacol. 1990; 37: 996–1004
- Stickle D., Barber R. Evidence for the role of epinephrine binding frequency in activation of adenylate cyclase. Mol. Pharmacol. 1989; 36: 437–445
- Stickle D., Barber R. Comparisons of the combined contributions of agonist binding frequency and intrinsic efficiency to receptor-mediated activation of adenylate cyclase. Mol. Pharmacol. 1991; 40: 276–288